Dr. Veerle Verjans Nefroloog - Orpadt

More documents

Recommendations

Info

Incretin-effect Incretin effect is verminderd bij DM type 2 GLP-1 (pmol/L) 20 15 10 5 0 *p
Incretine-effect Incretine effect is verminderd bij DM type 2 Insulin (nmol liter –1 min) 60 50 40 30 20 10 0 7.4 *Low rate=0.4 pmol kg –1 min –1 **High rate=1.2 pmol kg –1 min –1 ***vs. corresponding NGT group NGT (n=9) Type 2 diabetes (n=9) Study included four examinations per patient: 1) an oral glucose challenge; and hyperglycemic clamp experiments with administration of 2) glucagon; 3) GIP; and 4) GLP-1. Only results for GLP-1 are shown. Adapted from Nauck MA et al J Clin Invest 1993;91:301–307. 51.4 GLP-1 infusion (low rate)* GLP-1 infusion (high rate)** P=NS*** 7.5 P=NS*** 38.2 Normale GLP-1 werking
Page 1 and 2: Dr. Veerle Verjans Nefroloog - diab
Page 3 and 4: Dr. Veerle Verjans Nefroloog - diab
Page 5 and 6: 1.Overzicht DM type 2 2.Incretines:
Page 7 and 8: Type 2 DM: gezondheidsprobleem * Me
Page 9 and 10: Pathofysiologie DM type2 Liver Exce
Page 11 and 12: klasse generische naam producten bi
Page 13 and 14: AANDACHT-AANDACHT AANDACHT AANDACHT
Page 15 and 16: R/ type 2 DM en gewichtstoename Cha
Page 17 and 18: Diabetes type 2, een ziekte met een
Page 19 and 20: GLP = glucagon like peptide ( jejun
Page 21 and 22: Fysiologie van incretines Beta-cell
Page 23: Incretine-effect Incretine effect i
Page 27 and 28: GLP-1 GLP 1 infusie bij DM type 2 S
Page 29 and 30: Incretines DPP-4 inhibitoren: (ora
Page 31 and 32: Exenatide (BYETTA) Synthetische ve
Page 33 and 34: Exenatide: Exenatide: verlaging Hba
Page 35 and 36: Hba1c < 7% blijft niet Median HbA 1
Page 37 and 38: R/ type 2 DM en gewichtstoename Cha
Page 39 and 40: Exenatide vs Insuline BYETTA: glyce
Page 41 and 42: Exenatide verbetert lipidenprofiel
Page 43 and 44: Nevenwerkingen Byetta Nausea Geef a
Page 45 and 46: AANDACHT-AANDACHT AANDACHT AANDACHT
Page 47 and 48: Liraglutide = Victoza 97% amino aci
Page 49 and 50: Liraglutide verlaagt gewicht ***p
Page 51 and 52: Liraglutide verlaagt post- prandial
Page 53 and 54: Exenatide LAR • 1 x per week subc
Page 55 and 56: Incretines DPP-4 inhibitoren: (ora
Page 57 and 58: DPP4 - gewicht stabiel Sitagliptin
Page 59 and 60: Exenatide vs Sitagliptine PPG (mg/d
Page 61 and 62: Nieuw algoritme voor type 2 DM (200
Page 63 and 64: Management of DM type 2 Life style
Page 65 and 66: Nieuw algoritme voor type 2 DM (200
Page 67 and 68: Behandelingskeuze type 2 DM Selecti
Page 73 and 74: Exenatide: Exenatide: verlaging Hba
Page 75 and 76:
Behandelingskeuze type 2 DM Selecti
Page 77 and 78:
Behandelingskeuze type 2 DM Selecti
Page 79 and 80:
AANDACHT-AANDACHT AANDACHT AANDACHT
Page 81 and 82:
Dr. Veerle Verjans Nefroloog - diab
Page 83 and 84:
Perorale medicatie Type 2 DM Maag-d
Page 85:
SGLT2-inhibitor: SGLT2 inhibitor: C
show all

Dr. Veerle Verjans Nefroloog - Orpadt

Create successful ePaper yourself

Delete template?

Save as template?